Hepatitis Monthly

Published by: Kowsar

Effect of Cytotoxic T Lymphocytes Induced by Recombinant Adeno-Associated Virus on Different Hepatitis B Virus Genes

Wu Guicheng 1 , An Xuan 1 , Xiang Yi 1 , Wei Fang 1 , Xia Lina 1 , Zhong Qing 1 , Du Biao 1 and Liu Yong 2 , *
Authors Information
1 Chongqing Three Gorges Central Hospital, Chongqing, 404000, China
2 Gene & Biotherapy Center, University of Arkansas for Medical Sciences, Little Rock, Arkansas 72205, USA
Article information
  • Hepatitis Monthly: May 2017, 17 (5); e42685
  • Published Online: November 27, 2016
  • Article Type: Research Article
  • Received: October 7, 2016
  • Revised: November 12, 2016
  • Accepted: November 20, 2016
  • DOI: 10.5812/hepatmon.42685

To Cite: Guicheng W, Xuan A, Yi X, Fang W, Lina X, et al. Effect of Cytotoxic T Lymphocytes Induced by Recombinant Adeno-Associated Virus on Different Hepatitis B Virus Genes, Hepat Mon. 2017 ; 17(5):e42685. doi: 10.5812/hepatmon.42685.

Copyright © 2016, Kowsar Corp. This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/) which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited.
1. Background
2. Objectives
3. Methods
4. Results
5. Discussion
  • 1. Terrault NA, Bzowej NH, Chang KM, Hwang JP, Jonas MM, Murad MH, et al. AASLD guidelines for treatment of chronic hepatitis B. Hepatology. 2016; 63(1): 261-83[DOI][PubMed]
  • 2. Liaw YF, Kao JH, Piratvisuth T, Chan HL, Chien RN, Liu CJ, et al. Erratum to: Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2012 update. Hepatol Int. 2012; 6(4): 809-10[DOI][PubMed]
  • 3. Hagiwara S, Nishida N, Kudo M. Antiviral therapy for chronic hepatitis B: Combination of nucleoside analogs and interferon. World J Hepatol. 2015; 7(23): 2427-31[DOI][PubMed]
  • 4. Minami M. Future therapy for hepatitis B virus infection. Clin J Gastroenterol. 2015; 8(4): 167-71[DOI][PubMed]
  • 5. Park JJ, Wong DK, Wahed AS, Lee WM, Feld JJ, Terrault N, et al. Hepatitis B Virus--Specific and Global T-Cell Dysfunction in Chronic Hepatitis B. Gastroenterology. 2016; 150(3): 684-95[DOI][PubMed]
  • 6. Chang KM, Liu M. Chronic hepatitis B: immune pathogenesis and emerging immunotherapeutics. Curr Opin Pharmacol. 2016; 30: 93-105[DOI][PubMed]
  • 7. Kim D, Lyoo KS, Smith D, Hur W, Hong SW, Sung PS, et al. Number of mutations within CTL-defined epitopes of the hepatitis B Virus (HBV) core region is associated with HBV disease progression. J Med Virol. 2011; 83(12): 2082-7[DOI][PubMed]
  • 8. Moreau A, Vandamme C, Segovia M, Devaux M, Guilbaud M, Tilly G, et al. Generation and in vivo evaluation of IL10-treated dendritic cells in a nonhuman primate model of AAV-based gene transfer. Mol Ther Methods Clin Dev. 2014; 1: 14028[DOI][PubMed]
  • 9. Pandya J, Ortiz L, Ling C, Rivers AE, Aslanidi G. Rationally designed capsid and transgene cassette of AAV6 vectors for dendritic cell-based cancer immunotherapy. Immunol Cell Biol. 2014; 92(2): 116-23[DOI][PubMed]
  • 10. Mahadevan M, Liu Y, You C, Luo R, You H, Mehta JL, et al. Generation of robust cytotoxic T lymphocytes against prostate specific antigen by transduction of dendritic cells using protein and recombinant adeno-associated virus. Cancer Immunol Immunother. 2007; 56(10): 1615-24[DOI][PubMed]
  • 11. You H, Liu Y, Cong M, Ping W, You C, Zhang D, et al. HBV genes induce cytotoxic T-lymphocyte response upon adeno-associated virus (AAV) vector delivery into dendritic cells. J Viral Hepat. 2006; 13(9): 605-12[DOI][PubMed]
  • 12. Liu Y, Chiriva-Internati M, You C, Luo R, You H, Prasad CK, et al. Use and specificity of breast cancer antigen/milk protein BA46 for generating anti-self-cytotoxic T lymphocytes by recombinant adeno-associated virus-based gene loading of dendritic cells. Cancer Gene Ther. 2005; 12(3): 304-12[DOI][PubMed]
  • 13. van der Aa E, Buschow SI, Biesta PJ, Janssen HL, Woltman AM. The Effect of Chronic Hepatitis B Virus Infection on BDCA3+ Dendritic Cell Frequency and Function. PLoS One. 2016; 11(8): 161235[DOI][PubMed]
  • 14. Wei MJ, Pan XN, Wei KP, Li XH, Liu XL, Zhang XM, et al. Efficacy of HBV-pulsed DCs in combination with entecavir in patients with chronic hepatitis B infection. Int Immunopharmacol. 2015; 27(2): 238-43[DOI][PubMed]
  • 15. Dai S, Zhuo M, Song L, Chen X, Yu Y, Zang G, et al. Lentiviral vector encoding ubiquitinated hepatitis B core antigen induces potent cellular immune responses and therapeutic immunity in HBV transgenic mice. Immunobiology. 2016; 221(7): 813-21[DOI][PubMed]
  • 16. Jing M, Wang J, Zhu S, Ao F, Wang L, Han T, et al. Development of a more efficient hepatitis B virus vaccine by targeting hepatitis B virus preS to dendritic cells. Vaccine. 2016; 34(4): 516-22[DOI][PubMed]
  • 17. Manzoor S, Saalim M, Imran M, Resham S, Ashraf J. Hepatitis B virus therapy: What's the future holding for us? World J Gastroenterol. 2015; 21(44): 12558-75[DOI][PubMed]
  • 18. Liu T, Song HL, Zheng WP, Shen ZY. Inhibition of HBV Replication in HepG2.2.15 Cells by Human Peripheral Blood Mononuclear Cell-Derived Dendritic Cells. Ann Clin Lab Sci. 2015; 45(5): 495-501[PubMed]
  • 19. Dai S, Zhuo M, Song L, Chen X, Yu Y, Tang Z, et al. Dendritic cell-based vaccination with lentiviral vectors encoding ubiquitinated hepatitis B core antigen enhances hepatitis B virus-specific immune responses in vivo. Acta Biochim Biophys Sin (Shanghai). 2015; 47(11): 870-9[DOI][PubMed]
  • 20. Borges da Silva H, Fonseca R, Cassado Ados A, Machado de Salles E, de Menezes MN, Langhorne J, et al. In vivo approaches reveal a key role for DCs in CD4+ T cell activation and parasite clearance during the acute phase of experimental blood-stage malaria. PLoS Pathog. 2015; 11(2): 1004598[DOI][PubMed]
  • 21. You CX, Shi M, Liu Y, Cao M, Luo R, Hermonat PL. AAV2/IL-12 gene delivery into dendritic cells (DC) enhances CTL stimulation above other IL-12 applications: Evidence for IL-12 intracrine activity in DC. Oncoimmunology. 2012; 1(6): 847-55[DOI][PubMed]
  • 22. Gil-Farina I, Di Scala M, Vanrell L, Olague C, Vales A, High KA, et al. IL12-mediated liver inflammation reduces the formation of AAV transcriptionally active forms but has no effect over preexisting AAV transgene expression. PLoS One. 2013; 8(7): 67748[DOI][PubMed]
  • 23. Gaudet D, Methot J, Dery S, Brisson D, Essiembre C, Tremblay G, et al. Efficacy and long-term safety of alipogene tiparvovec (AAV1-LPLS447X) gene therapy for lipoprotein lipase deficiency: an open-label trial. Gene Ther. 2013; 20(4): 361-9[DOI][PubMed]
  • 24. Buning H, Perabo L, Coutelle O, Quadt-Humme S, Hallek M. Recent developments in adeno-associated virus vector technology. J Gene Med. 2008; 10(7): 717-33[DOI][PubMed]
Creative Commons License Except where otherwise noted, this work is licensed under Creative Commons Attribution Non Commercial 4.0 International License .

Search Relations:



Create Citiation Alert
via Google Reader

Readers' Comments